Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies
NCT01203722Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2010
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus in hematologic malignancy (4 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Participants Who Have Severe Acute Graft-versus-host-disease (GVHD) at Day 100, Number of Participants Who Have Transplant-related Nonrelapse Mortality (NRM) at Day 100 and 1 more. Started Sep 2010; status: completed.
02
Drugs
sirolimus
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01203722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203722.